Increase in the Price of Cardiac Stents

1. At a Glance

• Cardiac/coronary stents (BMS and DES) are notified as scheduled drugs under Schedule-I of DPCO, 2013, making their prices regulator-fixed [S1][S2].
• The National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers revises ceiling prices using DPCO formulae; current ceilings are ₹10,692.69 (BMS) and ₹38,933.14 (DES) [S1].
• UPSC relevance: intersection of health affordability, price regulation, medical-device policy, and consumer protection — recurring GS-II/GS-III theme.

2. Why in the News

• PIB release dated 13 February 2026 clarified the present ceiling prices of coronary stents and reiterated NPPA's binding price cap on hospitals billing patients directly [S1].
• Follows continuous industry demand (esp. from DES makers/importers) to delist stents or raise the cap, citing innovation cost.

3. Background & Evolution

• July 2016: Coronary stents added to National List of Essential Medicines (NLEM) 2015 by Union Health Ministry [S2].
• 13 February 2017: NPPA's first ceiling price order — BMS ₹7,260 / DES (incl. BVS) ₹29,600, slashing market prices by up to 85% (BMS) and 74% (DES) [S2].
• 12 February 2018: NPPA notification mandating that hospitals, nursing homes, clinics performing angioplasty must bill stents at or below ceiling price (plus GST) [S1].
• Ceilings revised periodically via WPI-linked annual revision (Para 16, DPCO 2013) → current ₹10,692.69 / ₹38,933.14 [S1].

4. Core Static Facts

• Regulator: National Pharmaceutical Pricing Authority (NPPA), constituted 1997 under Dept. of Pharmaceuticals [S1].
• Parent Ministry: Ministry of Chemicals & Fertilizers (Dept. of Pharmaceuticals) — not Ministry of Health [S1].
• Enabling law: Drugs (Prices Control) Order, 2013 issued under Section 3 of the Essential Commodities Act, 1955 [S1].
• Schedule: Coronary stents listed in Schedule-I, DPCO 2013 [S1].
• Categories regulated: Bare Metal Stents (BMS) and Drug Eluting Stents (DES) (BVS/bioresorbable was earlier clubbed with DES) [S1][S2].
• Current ceiling prices: BMS ₹10,692.69; DES ₹38,933.14 (plus GST) [S1].
• Coverage: Applicable across India to all manufacturers, marketers, importers, and hospitals billing patients directly [S1].
• Penalty mechanism: Overcharging recoverable with 18% interest under DPCO 2013.

5. Multi-Dimensional Analysis

Economic - Initial 2017 cap delivered up to 85% price reduction (BMS) and 74% (DES), lowering out-of-pocket cardiac care costs [S2]. - NLEM-2022-linked price fixation generated annual patient savings ~₹3,788 crore (broader NLEM, not stents alone) [S3]. - Tension with industry: foreign DES makers (e.g., Abbott, Medtronic) have sought withdrawal of high-end stents citing unviable margins.

Social / Health-Equity - CVDs cause ~28% of India's deaths (NCD burden); angioplasty volume ~6 lakh procedures/year — price cap is pro-poor and pro-middle-class. - Direct-billing rule (Feb 2018) prevents hospitals from absorbing the cap into procedure charges [S1].

Legal / Constitutional - Anchored in Essential Commodities Act, 1955 → DPCO 2013; aligns with Article 21 (right to health, jurisprudence flowing from Paschim Banga Khet Mazdoor Samity v. State of WB). - Article 47 DPSP: State duty to raise nutrition and public health.

Scientific / Technological - Distinction: BMS (stainless steel scaffolds) vs DES (anti-proliferative drug coating like sirolimus/everolimus) vs BVS/Bioresorbable (dissolvable polymer — withdrawn globally post-ABSORB trial). - Innovation concern: cap may slow entry of next-gen stents; counter-argument: domestic manufacturers (Sahajanand, Meril) have scaled up.

Administrative / Governance - Implementation friction: hospitals unbundling stent cost into procedure/consumables to bypass cap. - Trade Margin Rationalisation (TMR) is the alternative regulatory tool now used for non-scheduled devices [S4].

6. Recent Developments (last 12-18 months)

• 13 Feb 2026 (PIB): NPPA reaffirmed ceiling prices ₹10,692.69 (BMS) and ₹38,933.14 (DES) and the 2018 hospital-billing notification [S1].
• Ongoing PIB clarifications (2025-26) on trade-margin rationalisation for essential medical devices and DPCO scheduled formulations [S4][S3].
• NLEM 2022 launch by Union Health Minister continues to drive Schedule-I expansion [S3].

7. Prelims Hooks

• NPPA functions under Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers — NOT Ministry of Health [S1].
• DPCO 2013 is issued under Section 3, Essential Commodities Act, 1955 [S1].
• Coronary stents added to NLEM 2015 in July 2016 [S2].
• First stent price cap notified on 13 February 2017 [S2].
• Initial caps: BMS ₹7,260; DES/BVS ₹29,600 [S2].
• Current caps: BMS ₹10,692.69; DES ₹38,933.14 [S1].
• Reduction at first cap: up to 85% for BMS, 74% for DES [S2].
• Hospitals billing patients directly must comply per NPPA notification dated 12 February 2018 [S1].
• Stents are in Schedule-I of DPCO 2013 [S1].
• Ceiling prices are pan-India and exclusive of GST [S1].
• NPPA was constituted in 1997.
• DES = stents with anti-proliferative drug coating (e.g., sirolimus/everolimus).

8. Mains Relevance

• GS-II: Issues relating to development and management of Health; Government policies and interventions; Regulatory bodies.
• GS-III: Indian Economy — issues of growth, distribution; pharma sector; consumer protection.
• Plausible question stems: 1. "Price control alone cannot guarantee affordable healthcare; structural reforms in the medical-device ecosystem are essential." Discuss in light of NPPA's stent price ceiling. 2. Evaluate the role of DPCO, 2013 and NPPA in balancing affordability of essential medicines with innovation incentives for manufacturers. 3. Discuss the federal and administrative challenges in enforcing ceiling prices of medical devices at hospital level.

9. Related Topics to Study Next

• DPCO 2013 & NLEM 2022 — parent regulatory framework.
• National Pharmaceutical Pricing Authority (NPPA) — institutional mandate, paragraph 19 powers.
• Essential Commodities Act, 1955 — constitutional/statutory base.
• Ayushman Bharat — PM-JAY — package rates for cardiac procedures intersect with stent pricing.
• Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — affordable generics.
• Trade Margin Rationalisation (TMR) for non-scheduled devices — alternative tool.
• Medical Devices Rules, 2017 (CDSCO) — quality regulation counterpart.
• NCD Burden & NPCDCS — demand-side context for cardiac care.

10. Common Errors / Trap Areas

• Placing NPPA under Ministry of Health — it is under Ministry of Chemicals & Fertilizers (DoP) [S1].
• Confusing DPCO Schedule-I (price control) with NLEM (essentiality list, Health Ministry) — both exist; Schedule-I largely mirrors NLEM.
• Assuming ceiling prices are inclusive of GST — they are exclusive of GST [S1].
• Forgetting that hospitals, not just manufacturers, are bound by the ceiling (per 12 Feb 2018 notification) [S1].
• Mixing up BVS/Bioresorbable scaffolds with a separate price tier — they were clubbed under DES initially [S2].

11. Sources

• [S1] Increase in the Price of Cardiac Stents — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2227619 — (tier 1)
• [S2] Stent Price Cap - A Bold Pro-People Step — https://www.pib.gov.in/newsite/printrelease.aspx?relid=161440 — (tier 1)
• [S3] Average price reduction under NLEM 2022 (₹3,788 cr savings) — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2112308&reg=3&lang=2 — (tier 1)
• [S4] Issue of high trade margins in essential medical devices — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241169&reg=3&lang=2 — (tier 1)